The company has withdrawn all litigation against Vikas Lifecare Limited post withdrawal of the Alwar Case by VLL
Glenmark’s Clindamycin Phosphate Foam, 1% is bioequivalent and therapeutically equivalent to Evoclin Foam, 1%, of Mylan Pharmaceuticals.
Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries
Next-generation lens features purely refractive design, delivering uninterrupted high-quality vision with high best-in-category contrast & low-light performance
The company will offer end-to-end services and solutions for the sector with a specific focus on sustainability
Ipratropium Bromide Nasal Solution is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis
Peter Bains has over three decades of experience in the biotech and pharmaceutical industry
_256_384.jpg)
Hikal Limited announces the completion of the US Food and Drug Administration (USFDA) inspection at its Jigani unit, Bengaluru
During the quarter, the company posted Revenue from operations at Rs. 5,269 crore as compared to Rs. 4,505 crore in Q3 FY25, posting a growth of 17 per cent
Wockhardt also saw its revenue from operations increased 3% to Rs. 721 crore during Q3 FY25
Subscribe To Our Newsletter & Stay Updated
